A First-in-Class Approach to Treating a Rare and Chronic Liver Disease
RARECast - Un pódcast de RARECast - Jueves
Categorías:
Sujal Shah, president and CEO of CymaBay Therapeutics, discusses the rare and chronic livers disease primary biliary cholangitis, Seladelpar, and why this first-in-class therapy has promise for addressing a condition with high unmet needs.
